Business Context and Reporting Period
This Form 8-K reports on the reconvened 2024 Annual Meeting of Stockholders for GRI Bio, Inc., held on September 6, 2024. The meeting was previously adjourned on August 23, 2024. As of the record date of June 27, 2024, the company had 741,914 shares of common stock issued and outstanding eligible to vote. A quorum of 311,668 shares (approximately 42% of eligible shares) was present.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Four proposals were voted upon at the reconvened meeting:
- Proposal 1 (Election of Director): David Baker was elected as a Class I director. He received 61,134 votes for, 40,091 votes against, and 155 abstentions.
- Proposal 2 (Auditor Ratification): The appointment of Sadler, Gibb & Associates LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. It received 285,641 votes for, 25,988 votes against, and 39 abstentions.
- Proposal 3 (Share Issuance Approval): Shareholders approved the issuance of shares underlying Series C-1 and C-2 Common Warrants and Placement Agent Warrants, exceeding 20% of outstanding common stock to comply with Nasdaq Rule 5635(d). It received 51,165 votes for, 47,971 votes against, and 2,244 abstentions.
- Proposal 4 (Equity Plan Amendment): The proposal to increase the aggregate number of shares available under the Amended and Restated 2018 Equity Incentive Plan by 600,000 was rejected. It received 31,556 votes for, 68,911 votes against, and 913 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on financial performance, or new risk factors. The document references the Definitive Proxy Statement filed on August 2, 2024, for detailed descriptions of the matters voted upon.
Key Facts for Investor Verification
- Verify the impact of the rejection of Proposal 4 on the company's ability to grant equity incentives to employees and directors.
- Confirm the total number of shares to be issued under the approved warrants in Proposal 3 and the resulting dilution to existing shareholders.
- Review the Definitive Proxy Statement for the rationale behind the election of David Baker and the specific terms of the auditor appointment.
- Monitor future filings for any revised proposals regarding the Equity Incentive Plan following the shareholder rejection.